ERBB2 and breast carcinoma: To verify this result in a bigger patient cohort, we analysed miR-184 expression in the METABRIC cohort of 980 breast cancers [31] and also observed that miR-184 mean expression was highest in HER2-positive breast cancers and significantly lower in basal breast cancers, a subset of TNBC (Fig. 6b).